Ventyx Biosciences (VTYX) – Research Analysts’ Weekly Ratings Updates

Ventyx Biosciences (NASDAQ: VTYX) recently received a number of ratings updates from brokerages and research firms:

• 11/7/2025 – Ventyx Biosciences had its price target raised by analysts at Canaccord Genuity Group Inc. from $14.00 to $16.00. They now have a “buy” rating on the stock.
• 11/7/2025 – Ventyx Biosciences had its price target raised by analysts at Wells Fargo & Company from $11.00 to $14.00. They now have an “overweight” rating on the stock.
• 11/5/2025 – Ventyx Biosciences was upgraded by analysts at HC Wainwright from a “neutral” rating to a “buy” rating. They now have a $18.00 price target on the stock.
• 10/27/2025 – Ventyx Biosciences had its price target raised by analysts at Oppenheimer Holdings, Inc. from $9.00 to $14.00. They now have an “outperform” rating on the stock.
• 10/8/2025 – Ventyx Biosciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Ventyx Biosciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.